Several pharmaceutical companies have pursued development of GCGR antagonists (using various molecular formats), which have been shown to improve glucose regulation without increasing the risk of hypoglycaemia in patients with type 1 diabetes as well as those with type 2 diabetes [40]. This evidence concerns the gene GCGR and Hypoglycemia.